Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure

Overview

Journal Clin Interv Aging

Publisher Dove Medical Press

Specialty Geriatrics

Date 2020 May 6

PMID 32368021

Citations 7

Authors

Alexandra Dadarlat-Pop

Adela Sitar-Taut

Dumitru Zdrenghea

Bogdan Caloian

Raluca Tomoaia

Dana Pop

Anca Buzoianu

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: In Romania, robust data about the prevalence of obesity and heart failure are lacking, especially in the elderly; therefore, this study aims to analyze the profile of overweight and obese patients aged >65 years admitted to a Romanian hospital for worsening heart failure, and also their risk in the presence of comorbidities.

Patients And Methods: This cross-sectional study was conducted in 126 consecutive elderly patients with overweight and obesity admitted to a Romanian hospital for worsening heart failure. They were divided into three groups: with reduced (<40%) - HFrEF, mid-range (40-49%) - HFmrEF and preserved (≥50%) ejection fraction - HFpEF. Obesity was defined according to the body mass index (BMI) status: obesity, ≥30 kg/m; overweight, 25-29.9 kg/m. The Charlson Comorbidity Index (CCI) was calculated to evaluate the severity of comorbidity, with a score ranging from 2 (only heart failure present and age >65 years) to 30 (extensive comorbidity).

Results: NT-proBNP values are negatively correlated with BMI only in patients with HFpEF. Creatinine clearance (p=0.0166), the presence of atrial fibrillation (p=0.0095) and NYHA functional class were independent predictors of increased NT-proBNP values. CCI score is negatively correlated with NT-proBNP values in patients with HFmrEF (r= -0.448, p=0.009) and HFpEF (r= -0.273, p=0.043). The CCI risk was not significantly different between the three groups.

Conclusion: Elderly heart failure patients with overweight or obesity have particular characteristics in terms of NT-proBNP values and presence of comorbidities. In the studied population, NT-proBNP levels were strongly influenced by renal function, NYHA functional class, the presence of atrial fibrillation and left ventricular ejection fraction.

Citing Articles

The effect of probiotic-fortified kefir on depression, appetite, oxidative stress, and inflammatory parameters in Iranian overweight and obese elderly: a randomized, double-blind, placebo-controlled clinical trial.

Noori M, Shateri Z, Babajafari S, Eskandari M, Parastouei K, Ghasemi M J Health Popul Nutr. 2025; 44(1):30.

PMID: 39920878 PMC: 11806806. DOI: 10.1186/s41043-025-00773-x.

Prognostic Value of Myocardial Function Imaging Markers in Elderly Patients Undergoing Transcatheter Aortic Valve Replacement.

Dadarlat-Pop A, Molnar A, Serban A, Tomoaia R, Hagiu C, Manole S Clin Interv Aging. 2023; 18:1597-1606.

PMID: 37786426 PMC: 10541530. DOI: 10.2147/CIA.S413426.

Ejection fraction at hospital admission stratifies mortality risk in HFmrEF patients aged ≥ 70 years: a retrospective analysis from a tertiary university institution.

Sonaglioni A, Lonati C, Behring M, Nicolosi G, Lombardo M, Harari S Aging Clin Exp Res. 2023; 35(8):1679-1693.

PMID: 37277547 PMC: 10241373. DOI: 10.1007/s40520-023-02454-3.

Persimmon Proanthocyanidins with Different Degrees of Polymerization Possess Distinct Activities in Models of High Fat Diet Induced Obesity.

Yu Y, Chen P, Li X, Shen S, Li K Nutrients. 2022; 14(18).

PMID: 36145094 PMC: 9505881. DOI: 10.3390/nu14183718.

Interrelationship between Vitamin D and Calcium in Obesity and Its Comorbid Conditions.

Harahap I, Landrier J, Suliburska J Nutrients. 2022; 14(15).

PMID: 35956362 PMC: 9370653. DOI: 10.3390/nu14153187.

References

Yagawa M, Nagatomo Y, Izumi Y, Mahara K, Tomoike H, Shiraishi Y . Effect of Obesity on the Prognostic Impact of Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. Circ J. 2017; 81(7):966-973. DOI: 10.1253/circj.CJ-16-1130. View

Carbone S, Lavie C, Arena R . Obesity and Heart Failure: Focus on the Obesity Paradox. Mayo Clin Proc. 2017; 92(2):266-279. DOI: 10.1016/j.mayocp.2016.11.001. View

Sandhu R, Ezekowitz J, Andersson U, Alexander J, Granger C, Halvorsen S . The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016; 37(38):2869-2878. DOI: 10.1093/eurheartj/ehw124. View

Zheng L, Wu L, Yao Y, Chen W, Bao J, Huang W . Impact of body mass index on plasma N-terminal ProB-type natriuretic peptides in Chinese atrial fibrillation patients without heart failure. PLoS One. 2014; 9(8):e105249. PMC: 4140742. DOI: 10.1371/journal.pone.0105249. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Peng Q, Hu W, Su H, Yang Q, Cheng X . Levels of B-type natriuretic peptide in chronic heart failure patients with and without diabetes mellitus. Exp Ther Med. 2012; 5(1):229-232. PMC: 3523957. DOI: 10.3892/etm.2012.760. View

Peralta M, Ramos M, Lipert A, Martins J, Marques A . Prevalence and trends of overweight and obesity in older adults from 10 European countries from 2005 to 2013. Scand J Public Health. 2018; 46(5):522-529. DOI: 10.1177/1403494818764810. View

Jhund P . Obesity and heart failure: when 'epidemics' collide. Eur Heart J. 2017; 38(24):1934-1936. DOI: 10.1093/eurheartj/ehw357. View

Lavie C, De Schutter A, Parto P, Jahangir E, Kokkinos P, Ortega F . Obesity and Prevalence of Cardiovascular Diseases and Prognosis-The Obesity Paradox Updated. Prog Cardiovasc Dis. 2016; 58(5):537-47. DOI: 10.1016/j.pcad.2016.01.008. View

10.

Gilbert R, Krum H . Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015; 385(9982):2107-17. DOI: 10.1016/S0140-6736(14)61402-1. View

11.

Richards A . The Relationship of Plasma NT-proBNP to Age and Outcomes in Heart Failure. JACC Heart Fail. 2016; 4(9):746-8. DOI: 10.1016/j.jchf.2016.06.006. View

12.

Montero D, Flammer A . Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy?. Eur J Heart Fail. 2017; 19(8):971-973. DOI: 10.1002/ejhf.811. View

13.

Saeed A, Ballantyne C . Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Curr Cardiol Rep. 2017; 19(3):19. DOI: 10.1007/s11886-017-0831-4. View

14.

Padwal R, McAlister F, McMurray J, Cowie M, Rich M, Pocock S . The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes (Lond). 2013; 38(8):1110-4. DOI: 10.1038/ijo.2013.203. View

15.

Wang H, Si Q, Shan Z, Guo Y, Lin K, Zhao X . Effects of body mass index on risks for ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation patients: a single-center experience. PLoS One. 2015; 10(4):e0123516. PMC: 4388788. DOI: 10.1371/journal.pone.0123516. View

16.

Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll M . The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 2009; 133(1):14-23. DOI: 10.1309/AJCP60HTPGIGFCNK. View

17.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

18.

Takase H, Dohi Y . Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2013; 44(3):303-8. DOI: 10.1111/eci.12234. View

19.

Clodi M, Resl M, Neuhold S, Hulsmann M, Vila G, Elhenicky M . A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. Eur J Prev Cardiol. 2011; 19(5):944-51. DOI: 10.1177/1741826711420015. View

20.

Filippatos G, Khan S, Ambrosy A, Cleland J, Collins S, Lam C . International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015; 17(5):527-33. PMC: 5024037. DOI: 10.1002/ejhf.262. View